Navigation Links
Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing
Date:5/21/2008

> enriched for the presence of EGFR mutations: Results from phase 2"

Day: Sunday, June 1

Session: Lung Cancer -- Metastatic

Time: 2-6 p.m.

Location: S Hall A1

Poster Number: 42H Abstract Number: 8053

Presenter: Naiyer A Rizvi, MD

Monday, June 2

-- XL647 (EGFR, HER2, VEGFR2) -- Poster & Discussion

"Activity and tolerance of XL647 in NSCLC patients with acquired

resistance to EGFR-TKIs: Preliminary results of a phase 2 trial"

Day: Monday, June 2

Session: Lung Cancer -- Metastatic

Time (Poster): 8 a.m.-noon Location: W375e Lobby

Time (Discussion): Noon-12:15 p.m. Location: W375d

Poster Number: 9 Abstract Number: 8028

Presenter: Vincent A. Miller, MD

-- XL880* (MET, VEGFR2) -- Poster

"Preliminary activity of GSK1363089 (XL880), a dual MET/VEGFR2

inhibitor, in MET amplified poorly differentiated gastric cancer

(PDGC): Interim results of a multicenter phase 2 study"

Day: Monday, June 2

Session: Gastrointestinal (Noncolorectal) Cancer

Time: 8 a.m.-noon

Location: S Hall A1

Poster Number: 33D Abstract Number: 4572

Presenter: Minaxi P. Jhawer, MD

* XL880 was selected by GlaxoSmithKline in December 2007 for further

development and commercialization.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)...ected to aid drug discovery by allowing for the ra...gle reaction, ST. LOUIS, Oct. 7 /PRNewswire-First...o announce that it has signed an exclusive licensi...bana-Champaign allowing,Sigma-Aldrich to offer res...ogates for use in Suzuki-Miyaura coupling to resea...
(Date:10/7/2008)...s to focus on new patient data supporting the Ross...ynerGraft processed human heart .../- CryoLife, Inc. (NYSE: C...ocessing company, announced today,that cardiovascu...e in the,Ross Summit 2008, a two-day surgical cong...
(Date:10/7/2008)...Institutes of Health, The Infectious Disease Resea...Launch and Board of Advisors, SEATTLE, Oct. 7 /PR...,Initiative today announced its first acquisition ...osis (TB) drug candidates. Agreements were reached...nd the Microbial Chemistry,Research Foundation (MC...
(Date:10/7/2008)... Oct. 7 /- BioEnergy International, L...r and manufacturer of,next-generation, renewable b...f Norman R. Augustine to its Board of Advisors eff...f distinguished leadership and innovation,at the h...g in his role as,Chairman and Chief Executive Offi...
Breaking Biology Technology:Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement 2Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement 3CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure 2CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure 3CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure 4Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 2Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 3Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 4Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 5BioEnergy International, LLC Announces Norman R. Augustine to Join Advisory Board 2BioEnergy International, LLC Announces Norman R. Augustine to Join Advisory Board 3
...eenah, Wis. - Thanks to a classified contract fro...alization company headquartered here, reported rec...rter ended July 1, 2006, despite the closing of it...y,s financial picture is tempered, however, by for...th quarter, which caused its stock price to fall b...
...ditor,s note: This article first appeared in Gene...ere is good news for inventors. Using an invention...ger than a year, will not by itself cause a court ...invention. , ,This rule was pronounced in response...nt asserted that the patent was invalid due to pri...
...auwatosa, Wis. - Personalized medicine is a conce...but people in the know believe so-called genetic-b...ic-based medicine, personal genetic profiles will ...o various diseases, and to develop disease managem...vironmental characteristics. , , Stephens Crack...
... shkosh, Wis. - BidRx , a new online company th...iption medications, is attempting to create a new ... has gone live with its new web site, where consum...are costs and obtain other information about presc...e for their medications out of pocket, the site,s ...
Other Biology Technology:Defense contract helps Plexus gain record profits 2With patents and research tools, when is private really public? 2With patents and research tools, when is private really public? 3With patents and research tools, when is private really public? 4With patents and research tools, when is private really public? 5Medical College researcher working to make genetic-based medicine a reality 2Medical College researcher working to make genetic-based medicine a reality 3Will BidRx start a drug price war? 2Will BidRx start a drug price war? 3Will BidRx start a drug price war? 4
(Date:10/7/2008)...nsional. That,s true even in the laboratory, where...evelop and what happens when their growth is abnor...o develop three-dimensional cell culture systems t...ugs in a system that more closely mimics the way i...is the cost of commercial media for growing such c...
(Date:10/7/2008)... Li Lab has characterized a mechanism that allows ...ocytes. By tracking chromosome movement in live mo...can recruit to their vicinity a protein called for...e majority of the cytoplasm a requirement for emb...other daughter cell (called a polar body) resultin...
(Date:10/7/2008)... 2008 Burnham Institute for Medical Research toda... that binds to Bcl-2, a protein that protects canc...it into a cancer cell killer. The research, which ...er 7 edition of Cancer Cell , may lead to new can...n implicated in protecting cancer cells from apopt...
(Date:10/6/2008)...mption of red wine may decrease the risk of lung c... issue of Cancer Epidemiology, Biomarkers & Preve...ancer Research. , "An antioxidant component in ...larly among smokers," said Chun Chao, Ph.D., a res...of Research and Evaluation in Pasadena, California...
Breaking Biology News(10 mins):Egg whites solve the 3-D problem 2Red wine may lower lung cancer risk 2ULURU Inc Announces the Launch Plan for Altrazeal 28TM 29 18793 1ULURU Inc Announces the Launch Plan for Altrazeal 28TM 29 18793 2ULURU Inc Announces the Launch Plan for Altrazeal 28TM 29 18793 3Susan G Komen for the Cures 28R 29 Moddelmog Calls for Congress to Launch Colossal Cancer Crusade 18788 1Susan G Komen for the Cures 28R 29 Moddelmog Calls for Congress to Launch Colossal Cancer Crusade 18788 2Susan G Komen for the Cures 28R 29 Moddelmog Calls for Congress to Launch Colossal Cancer Crusade 18788 3Alpharma Presents Data Addressing Abuse Liability Features Safety and Efficacy on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release wi 2014 1Alpharma Presents Data Addressing Abuse Liability Features Safety and Efficacy on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release wi 2014 2Alpharma Presents Data Addressing Abuse Liability Features Safety and Efficacy on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release wi 2014 3Alpharma Presents Data Addressing Abuse Liability Features Safety and Efficacy on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release wi 2014 4Alpharma Presents Data Addressing Abuse Liability Features Safety and Efficacy on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release wi 2014 5Alpharma Presents Data Addressing Abuse Liability Features Safety and Efficacy on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release wi 2014 6Alpharma Presents Data Addressing Abuse Liability Features Safety and Efficacy on ALO 01 28EMBEDA 28TM 29 29 28morphine sulfate extended release wi 2014 7Scientists identify key roadblock to gene expression 18781 1Scientists identify key roadblock to gene expression 18781 2
...itive tissue throughout the body have an undesirab...ions away. To overcome this hurdle, Johns Hopkins ... with a chemical that helps them slip through this...e coated particles, the researchers also discovere...eviously thought, providing a doorway that should ...
... able to eat prawns without the fear of an adverse...ng step towards removing from prawns the proteins ...to genetic manipulation, reports Lisa Richards in ... , Li Zhenxing led the research at the Ocean Unive...awns with a combination of heat and irradiation si...
...ty School of Medicine has helped confirm the reli...shering in the long-promised era of personalized .... , The Stanford group was one of the five sites t...entify patients who are at high risk of developin...at means high-risk patients could be directed tow...
...ill reveal in the 29 March 2007 issue of the journ...of important structures that control how genes are...e. "For the first time, we are seeing in very hig...s control the expression of an organism,s genes," ...nd molecular biology and the study,s lead investig...
Other Biology News:Coated nanoparticles solve sticky drug-delivery problem 2Coated nanoparticles solve sticky drug-delivery problem 3New test helps identify hepatitis C patients at high risk of developing cirrhosis 2New test helps identify hepatitis C patients at high risk of developing cirrhosis 3Scientists reveal structure of gateways to gene control 2Scientists reveal structure of gateways to gene control 3Scientists reveal structure of gateways to gene control 4
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface.
Antibeta-lactoglobulin monoclonal antibody(CD-2)
MAb to Vasopressin Preservative: NaN3
...α, clone 8G8/5 GenBank Accession Number : N...lpha/gamma fusion protein corresponding to residue...0 of human AP-2γ Formulation: 0.1M Tris-glyc... the addition of glycerol to 30% Quality Assurance...
Biology Products: